🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Rentomojo posts Rs 266 Cr revenue in FY25; profits surge 92%

EntrackrEntrackr · 1m ago
Rentomojo posts Rs 266 Cr revenue in FY25; profits surge 92%
Medial

Rentomojo posts Rs 266 Cr revenue in FY25; profits surge 92% Following strong momentum in the previous year, furniture and appliances rental startup Rentomojo reported a 38% year-on-year increase in revenue in FY25, while its profit surged 92% during the same period. Rentomojo’s revenue from operations rose to Rs 266 crore in FY25, compared to Rs 193 crore in FY24, according to a company statement released on Monday. Founded in 2014, Rentomojo operates at the intersection of consumer tech and lifestyle, offering furniture, appliances, and newer categories such as water purifiers on a rental basis. The company currently serves over 2.2 lakh live subscribers, manages more than 7.7 lakh rental items, and operates across 23 cities through 71 experience stores. The company said its net rental revenue grew at a 48.24% CAGR between FY23 and FY25, while EBITDA increased to Rs 118.41 crore in FY25 from Rs 78.23 crore in FY24, reflecting improved operating leverage. Founder and CEO Geetansh Bamania attributed the improved performance to disciplined execution, automation, and a refurbishment-led operating model. “Rentomojo is a consumer tech company building a subscription-first model that has delivered sustained profitability while solving a major problem for its consumers,” he said. According to the company, its return on capital employed (ROCE) stood at 25.1% in FY25, driven by reinvestment into refurbishment, automation, and capital efficiency. Rentomojo added that its circular economy-led approach, focused on reuse and sustainability, has helped improve asset utilisation and long-term resilience. Rentomojo has raised over Rs 650 crore across multiple funding rounds, including its latest $25 million round led by Edelweiss. Notable investors include Accel, Chiratae Ventures, Bain Capital, along with Edelweiss Discovery Fund and ValueQuest S.C.A.L.E. Fund. The company is also supported by banks and NBFCs. The startup competes with players such as Furlenco, Rentickle, Cityfurnish, and to some extent, Pepperfry. According to media reports, the firm is also preparing for an initial public offering (IPO).

Molbio Diagnostics posts Rs 1,020 Cr revenue, Rs 138 Cr PAT in FY25

EntrackrEntrackr · 5m ago
Molbio Diagnostics posts Rs 1,020 Cr revenue, Rs 138 Cr PAT in FY25
Medial

Goa-based molecular diagnostics firm Molbio closed FY25 with Rs 1,020 crore in revenue and Rs 138.5 crore profit, marking a sharp recovery from its post-COVID slump. The Temasek-backed unicorn, which had shot into the limelight during the pandemic, saw its revenue peak at Rs 1,272 crore in FY21 before crashing to Rs 332 crore in FY23. According to its draft red herring prospectus (DRHP) filed with SEBI, Molbio’s scale grew 22% from Rs 836 crore in FY24 while its profits surged 66% during FY25, underlining the company’s turnaround ahead of its proposed public listing. The growth was largely powered by its flagship Truenat platform, a portable, battery-operated molecular testing system used for tuberculosis and over 30 other infectious diseases. As per the DRHP, the company claims to have sold 2,180 devices with 12.24 million test kits in FY25. Molbio’s total expenses grew 25% to Rs 820 crore in FY25. Raw material consumption accounted for more than half of the cost base at Rs 413 crore, while employee benefits rose 61% to Rs 103 crore. Advertising and marketing spend nearly doubled to Rs 22 crore. At the same time, the company’s EBITDA margin stood at 26.17% while return on capital employed (ROCE) was at 22.06% in FY25. On a unit level, it spent Rs 0.80 to earn a rupee of revenue, compared to Rs 0.82 in FY24. The company currently operates five manufacturing units across Goa, Bengaluru, and Visakhapatnam, with an installed capacity of 3,600 Truenat devices and 3.9 crore test kits annually. Backed by Temasek and Motilal Oswal Private Equity, Molbio has raised about Rs 970 crore to date. Through its IPO, Molbio plans to raise Rs 200 crore via a fresh issue, while existing shareholders will offload 1.25 crore shares through an offer for sale. The proceeds will be used for a new R&D facility, expansion of manufacturing units, and general corporate purposes. As per the DRHP, Exxora Trading LLP is the largest shareholder in Molbio with a 41.23% stake, followed by India Business Excellence Fund at 12.66%. Temasek owns 8.93%, while Gopalkrishna Mangalore Kini and Dr. Chandrasekhar Bhaskaran Nair hold 6.73% and 5.42%, respectively. Molbio has bounced back from its pandemic boom and later slump to steady growth and profits, making it one of the few healthcare startups ready to go public. Its IPO will be watched closely to gauge investor interest in diagnostics companies after COVID-19.

Download the medial app to read full posts, comements and news.